Viridian Therapeutics, Inc./DE (VRDN) Overview
- 1 Jul 2024: Period ending 30 Sept 2024; Estimate (m); Actual -1.15; Beat / miss (m).
- 1 Apr 2024: Period ending 30 Jun 2024; Estimate (m); Actual -1.02; Beat / miss (m).
- 1 Jan 2024: Period ending 31 Mar 2024; Estimate (m); Actual -0.79; Beat / miss (m).
- 1 Jul 2023: Period ending 30 Sept 2023; Estimate (m); Actual -1.09; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $28.49
- Previous close
- $20.00
- Change
- $8.49
- Change (%)
- 42.49%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- VRDN
- -35.75%
- S&P 500
- (m)
1 year
- VRDN
- -7.47%
- S&P 500
- (m)
3 years
- VRDN
- +30.35%
- S&P 500
- (m)
5 years
- VRDN
- +17.62%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Sept 2024 ○ Estimate (m) ● Actual -1.15
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jul 2024 | 30 Sept 2024 | (m) | -1.15 | (m) | (m) |
| 1 Apr 2024 | 30 Jun 2024 | (m) | -1.02 | (m) | (m) |
| 1 Jan 2024 | 31 Mar 2024 | (m) | -0.79 | (m) | (m) |
| 1 Jul 2023 | 30 Sept 2023 | (m) | -1.09 | (m) | (m) |
| 1 Apr 2023 | 30 Jun 2023 | (m) | -1.27 | (m) | (m) |
31 Dec 2023 ○ Estimate (m) ● Actual -5.31
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2023 | 31 Dec 2023 | (m) | -5.31 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | -4.05 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | -6.66 | (m) | (m) |
| 1 Jan 2020 | 31 Dec 2020 | (m) | -31.13 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
31 Mar 2018 ■ Revenue 4.78M ■ Earnings -4.66M — Profit margin -97.43%
31 Dec 2017 ■ Revenue 4.00M ■ Earnings -26.51M — Profit margin -662.30%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $28.49 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning VRDN
View more →(m)
Statistics
View more →Retained observations as of 2026-11-12; financial period ending 31 Mar 2018.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-24.19M
- Operating margin · 12 months
- -290.83%
- Profit margin
- -290.61%
- Return on assets · 12 month
- -33.42%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 252.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 1.69M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -9.61%*
- Total return · month
- -13.37%*
- Total return · quarter
- 6.41%*
- Total return · half year
- -27.00%*
- Total return · year to date
- -35.75%*
- Total return · 1 year
- -7.47%*
- Total return · 3 years
- 30.35%*
- Total return · 5 years
- 17.62%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- R&D / revenue · 12 months
- 263.26%
- Revenue · 12 month
- $8.32M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-27.34M
- Free cash flow · 12 months (USD)
- $-27.64M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Payables · latest quarter (USD)
- $760.00K
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
Viridian Therapeutics, Inc./DE Overview
View more →(m)
(m)
- SEC CIK
- 1590750
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- United States
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, Massachusetts, 02453, United States
- Fiscal year end
- 1231
- Phone
- 617.272.4600
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |